SUMMARY Liver dysfunction occurs after bone marrow transplantation but the relative importance of graft versus host disease and other factors, such as infection, radiation, and drugs, has not been clearly established. We have studied liver status before and after bone marrow transplantation in 43 consecutive patients and have related this to survival and factors that are recognised to cause liver injury. Minor abnormalities of liver tests occurred in 21% of patients before grafting but this did not influence survival or the development of liver disease after transplantation. During the first 50 days after grafting, 83% of patients had abnormal liver tests which were more severe in patients who subsequently died. Alanine transaminase was significantly higher in non-survivors and appeared to predict survival early after transplantation.
Hepatic dysfunction is a well-recognised feature of graft versus host disease (GVHD) complicating bone marrow transplantationl13 and usually occurs when there is already skin or gut involvement. GVHD can occur in up to 70% of successful allogeneic grafts2 4 5 and now accounts for many of the deaths after grafts for acute leukaemia. The development of severe liver disease has been reported6 7 but its prevalence and effect on survival remain uncertain. Hepatic dysfunction after bone marrow grafting is often attributed to GVHD but many other factors, such as previous hepatitis, chemotherapy, radiation, opportunistic infection, and drugs used to treat GVHD, are also likely to be important. Severe distrubance of liver function has commonly been associated with death after bone marrow transplantation at the Royal Marsden Unit and we have therefore made a retrospective study of from a cobalt source at 2.5 rad/min, after which bone marrow was infused intravenously. Patients grafted for aplastic anaemia were treated similarly, except that cyclophosphamide was given at 60 mg/kg for four days and they did not receive total body irradiation. On the day after transplantation oral methotrexate2 9 or cyclosporin Al0 or both were given as a prophylaxis against GVHD. After transplantation patients were nursed in reverse barrier isolation, ate sterile food, and received oral nonadsorbable antibiotics.'1 All transfused blood products were irradiated to 1500 rads. Clinical details with respect to age, initial diagnosis, previous chemotherapy and total body irradiation, GVHD, and liver histopathology are outlined in Tables 1 and  2 .
CLINICAL AND BIOCHEMICAL ASSESSMENT OF LIVER STATUS
A clinical history was taken with particular emphasis on drugs and previous hepatic disorders, particularly hepatitis. Overall liver status was assessed by a combined clinical and biochemical grading system, the details of which are shown in Table 3 Liver tests A rise in ALT (always less than 100 IUll) occurred in only nine of the 43 patients grafted, and was not associated with any abnormality of bilirubin or alkaline phosphatase. Abnormalities of ALT could not be related to any particular chemotherapeutic regimen and bore no relationship to survival or to the development of liver disease after bone marrow transplantation.
LIVER STATUS AFTER BONE MARROW TRANSPLANTATION
Liver status during the early and late posttransplantation periods is shown for both survivors and non-survivors in Fig. 1 . During the first 50 days after grafting, disturbance of liver tests occurred in 83% of patients. During this early period, differences were apparent between survivors and non-survivors. Forty per cent of the non-survivors had moderate to severe (grade II-IV) liver dysfunction compared with 18% of the survivors, none of whom had developed clinical signs of liver disease (grade IV).
In the later period (>50 days) after bone marrow transplantation this pattern persisted: 56% of the non-survivors had grade II-IV hepatic dysfunction compared with 12% of the survivors (grade II and III only). To examine the relationship between abnormalities of liver tests and survival after grafting we analysed serial estimations of bilirubin, ALT, and alkaline phosphatase during the first 100 days. Hyperbilirubinaemia above 30 iimol/l occurred only in non-survivors. Median alkaline phosphatase tended to rise throughout this period (Fig. 2 Tables 1   and 2 .
Atypia of the bile duct epithelium (Fig. 3 ) was 0 1 11 Ill lV present in eight patients and involved only small bile ducts. All of these patients had histological evidence of moderate to severe GVHD in the skin or gut, or both. In all but the mildest case, this bile duct lesion was associated with histological evidence of cholestasis, a mild lymphocytic infiltration, and a rise in serum alkaline phosphatase, although the latter was not significantly higher than in those patients without bile duct atypia. Four of these patients with bile duct atypia also had evidence of portal fibrosis. Focal hepatocyte necrosis was found in only four patients and in all cases the lesion was minor. In only one patient did it occur in association with the bile duct lesion. All the livers examined had evidence of moderate to severe siderosis. Evidence of veno-occlusive disease (Fig. 4) was found in two patients (nos. 36 and 40), both of whom were jaundiced by the 20th day after transplantation and had other liver test abnormalities. At this time one had evidence of skin GVHD, as did the other within a further five days. Both subsequently developed oedema, ascites, and hypoalbuminaemia, and died in hepatic failure. Both of these patients had received a variety of chemotherapeutic agents including cytosine arabinoside, 6-thioguanine, and adriamycin, both had severe GVHD, and both had had total body irradiation. 
Discussion
In the present study severe liver dysfunction occurred in seven of the 23 patients who died (30%) and in all of these the disturbance of liver function was thought to be either the cause or a major contributor to death. The prevalence is similar to that reported previously when nine of the 29 (31%) patients who died after bone marrow transplantation for aplastic anaemia had evidence of liver dysfunction,'5 one of whom was thought to have chronic aggressive hepatitis and the remainder GVHD involvement of the liver. The clinical state of these patients and the histological criteria for making the diagnosis of hepatic GVHD were not reported. Our retrospective study demonstrates that, during the first 50 days after grafting, mild disturbances of liver tests occur in the majority of patients but in survivors were limited to rises in ALT and alkaline phosphatase, whereas significant hyperbilirubinaemia above 30 ,umol/l was seen only in the non-survivors. During the later period after grafting (>50 days), liver tests tended to improve in survivors, whereas in non-survivors they deteriorated: 58% had moderate to severe liver dysfunction. Although we are reluctant to place undue emphasis on these liver tests, the proposal arising from this study-that abnormalities of the ALT may predict survival after bone marrow transplantation as early as 20 days after grafting-requires prospective evaluation.
While the aetiology of this abnormality is likely to be multifactorial, it does suggest that factors other than the bile duct disturbance of GVHD contribute to transplantation liver injury.
PRE-GRAFT DRUG THERAPY AND ACUTE HEPATITIS
Although many of the drugs used to treat acute leukaemia have been shown to be hepatotoxic,16 we were unable to find a relationship between the type or the extent of pre-graft chemotherapy and posttransplantation liver dysfunction. It is now apparent, however, that survival has been improved by grafting patients with acute myeloid leukaemia during their first remission.5 17 The reduced amount of chemotherapy that these patients have received may be an important factor in survival. Although 17 a-alkylated androgenic and anabolic steroids are known to cause hepatic damage,18 19 we found no correlation between previous androgen therapy and either survival or the propensity to develop liver dysfunction after grafting.
The effect of previous hepatitis on survival in the present study cannot be evaluated satisfactorily because of inadequate numbers of patients. However, it may be worth commenting that two of our three patients with post-hepatic aplastic anaemia died after grafting with severe hepatic GVHD and four of six patients with the same initial diagnosis in Seattle died, two of whom had liver complications.15
CONDITIONING REGIMEN FOR BONE MARROW
Although high-dose cyclophosphamide causes hepatic damage in animals,20 2 there is little evidence of severe hepatotoxicity in man. 22 Ionising radiation, however, is known to cause hepatitis, hepatic fibrosis,23 24 and hepatic veno-occlusive disease.25 In addition, hepatic tolerance to radiation is reduced when combined with certain drugs, particularly adriamycin,26 antinomycin D, and 5-fluoro-uracil.27 However, our patients with leukaemia received the same conditioning regimen so the specific effects of chemotherapy and radiation cannot be determined, but a recent study6 has demonstrated increased hepatotoxicity of conditioning regimens which included carmustine and busulfan. In our study, the prevalence of clinical liver disease was not significantly reduced in patients grafted for aplastic anaemia (conditioned without total body irradiation), although a direct comparison cannot be made, as these patients received more prolonged conditioning with cyclophosphamide.
GVHD GVHD occurred in 48% of the 40 patients who received allogeneic grafts and in 70% of the fatalities. Although there was a strong association between the occurrence of severe clinical liver disease and the presence of GVHD elsewhere, biochemical abnormalities were more common and occurred in 83% of the patients, suggesting that factors other than GVHD are responsible for hepatic dysfunction after bone marrow transplantation. The most striking histological feature in the liver associated with skin and gut GVHD was cellular atypia of small bile ducts which was almost invariably associated with cholestasis. This feature has been reported previously in man,3 13 Liver dysfunction after bone marrow transplantation is common and clearly a complex matter and it is unlikely that any single factor is responsible.
Severe liver disease after bone marrow transplantation, however, was always associated with GVHD alone or in combination with veno-occlusive disease. It would seem important that histological diagnostic criteria are established for hepatic GVHD and current evidence would favour bile duct atypia as the most useful. Liver test abnormality alone is insufficient to make a diagnosis of hepatic GVHD.
Drugs, radiation, or opportunistic infection can be important in some patients either alone or in combination. The cause of hepatic veno-occlusive disease and the abnormalities of hepatic reticulin remains uncertain, although chemotherapy for acute leukaemia and pre-graft conditioning regimens appear at present to be the most important factors. 
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